Martin Edwards

Martin Edwards, listed as senior executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Verona Pharma plc, Reata Pharmaceuticals Inc and Morphic Holding, Inc. Over a trading history stretching from 1 February 2021 to 7 October 2025, the count stands at 16 filings.

In open-market terms, that means 2 purchases worth €102k on one side and 3 sales worth €144k on the other. Netting one side against the other leaves €41k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 5 share grants and 2 option exercises. In 2025 alone, the filings show no purchases and 1 sale.

On 8 October 2025 came the latest disclosure, an option exercise in Verona Pharma plc. The latest purchase dates back some time: it was published 1,082 days ago, on 22 November 2023. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.